Latest Content

The deal strengthens Körber’s SAP supply chain and digital manufacturing consulting portfolio, extends its global footprint, and creates Körber Stellium to deliver end-to-end supply chain and software solutions.

In the second part of his Pharma Commerce video interview, Joe Hudicka, entrepreneur and supply chain expert, notes that in order to reduce risk and accelerate adoption, supply chain leaders can begin applying AI to machine-generated data—such as IoT sensor outputs—where insights improve performance without raising concerns about data ownership, security, or competitive exposure.

In today’s Pharma Pulse, a new national survey exposes the depth of America’s prescription access crisis, while AstraZeneca and Eli Lilly commit billions of dollars to next-generation weight-loss therapies and domestic manufacturing.

This guide breaks down how AFPs function and why they are fundamentally changing the path between patients and their therapies.

In the first part of his Pharma Commerce video interview, Joe Hudicka, entrepreneur and supply chain expert, explains how pharma leaders can detect early warning signs beyond their own silos and adapt before disruption becomes unavoidable.

In today’s Pharma Pulse, HHS issues guidance for manufacturer-direct drug discounts, while clinical data warns of significant weight regain after stopping tirzepatide and semaglutide.

For the first time, CMS has released negotiated prices for high-cost drugs covered under both Medicare Part D and Part B, naming 15 new negotiation targets and signaling continued efforts to rein in prescription drug spending.

Despite steady growth since the Drug Quality and Security Act, outsourcing facilities remain constrained in scale and scope, offering targeted mitigation rather than systemic relief for persistent shortages.

In today’s Pharma Pulse, the AAP defies federal vaccine cuts, Morris & Dickson scales its specialty footprint, and Insilico Medicine targets cardiometabolic health with a new partnership.

The acquisition strengthens M&D’s specialty portfolio, broadens access to plasma-derived therapies, and supports phased integration focused on regulatory compliance.

In today’s Pharma Pulse, extreme weather tests the resilience of community pharmacies, while CMS proposes a near-flat 0.09% update for Medicare Advantage and Part D payments in 2027.

The new Medicare payment model aims to take down wasteful spending, but Congress and analysts point out potential problems.

Even the threat of Greenland-related tariffs rattled drug supply chains and uncovered industry vulnerabilities to instability.